Search 33,000+ CME courses
Back

StatPearls, LLC

  • Calcineurin Inhibitors
  • Kidney Failure, Chronic
  • Lupus Erythematosus, Systemic
  • Lupus Nephritis
  • Proteinuria

Voclosporin

Voclosporin, a novel immunosuppressive medication, is approved for treating and managing lupus nephritis (LN) within the class of calcineurin inhibitors (CNIs). LN is a common manifestation of systemic lupus erythematosus (SLE), an autoimmune disease affecting various organs. Approximately 40% of SLE patients may develop LN. The primary goal of LN treatment is to preserve kidney function, reduce mortality, and improve the patient’s quality of life while minimizing treatment-related adverse events. A timely response to therapy, as indicated by a reduction in proteinuria, may predict long-term outcomes, including the risk of SLE flares, end-stage kidney disease, and mortality. In the United States, voclosporin received FDA approval in 2021 for treating active LN in adults, combined with background immunosuppressive therapy. This CME activity overviews the indications, actions, and contraindications for voclosporin. It also emphasizes the mechanism of action, adverse event profile, and key factors such as dosing, pharmacokinetics, contraindications, and monitoring that are essential for healthcare team members involved in treating patients with lupus nephritis using voclosporin.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AAPA Category 1 Credit™Up to 1 creditAMA PRA Category 1 Credit™Up to 1 creditNursingUp to 1 creditPharmacyUp to 1 credit

MOC types

ABS — Accredited CMEUp to 1 pointABPATH — Lifelong LearningUp to 1 pointABTS — Accredited CMEUp to 1 pointABIM — Medical KnowledgeUp to 1 pointABS — Self-AssessmentUp to 1 pointABP — Lifelong Learning and Self-AssessmentUp to 1 pointABTS — Self-AssessmentUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Cross-Specialty

Relevant across 6 specialties.

Pricing

Fee varies

This provider typically $49–98

See fees on statpearls.com

Listed by the provider

  • Article / monograph / reference
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Fee varies · this provider typically $49–98
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Sep 1, 2029 3 years left

Related courses

See all

Other providers’ courses on the same topic

More from StatPearls, LLC

See all

This provider’s courses closest to this one